Gilead saves US$10b in taxes as pricey hep C drug takes off
This boosts its already huge profits, letting firm stash even more billions in tax havens abroad, says advocacy group
Add BT as a preferred source
DeeperDive is a beta AI feature. Refer to full articles for the facts.
New York
GILEAD Sciences Inc's profit margin has soared and its tax rate has plummeted since the drugmaker introduced its controversial US$1,000-a- day medication for hepatitis C, according to a report by an advocacy group that accuses the company of using accounting gimmicks to stash billions in earnings in tax havens offshore.
By moving some of its intellectual property to Ireland, Gilead was able to employ a common strategy that cut its US tax bill by US$10 billion since 2013, according to Americans for Tax Fairness (ATF), a left-leaning think-tank.
Share with us your feedback on BT's products and services
TRENDING NOW
Ministry of Home Affairs Permanent Secretary Pang Kin Keong to retire
Shelving S$5 billion office redevelopment plan proved ‘wise’ as geopolitical risks mount: OCBC chairman
Richard Eu on how core values, customers keep Singapore’s TCM chain Eu Yan Sang relevant
China pips the US if Asean is forced to choose, but analysts warn against reading it like a sports result
